The BeAMS Study. Long-term benefits and adverse effects of beta-interferon for multiple sclerosis

Project number: 
Approval date: 
Thursday, November 26, 2009
Principal Investigator: 
University of British Columbia (UBC)
Funding Agency: 
Canadian Institutes of Health Research(CIHR),Canadian Institutes of Health Research(CIHR)
Datasets requested: 
consolidation - census geocodes
Hospital Separations (BC Ministry of Health)
ACG Case Mix Group (Johns Hopkins University)
Medical Services Plan (BC Ministry of Health)
Home and Community Care (BC Ministry of Health)
Consolidation - demographic (Ministry of Health)
Deaths (BC Vital Statistics Agency)
Research objective: 

Journal Publication

  • Zhang T, Kingwell E, De Jong H, Zhu F, Zhao Y, Carruthers R, Petkau J, Gustafson P, Oger J, Tremlett H. Association between selective serotonin reuptake inhibitors use and multiple sclerosis disability progression. Pharmacoepidemiology and Drug Safety [accepted 25-April-2016. Manuscript ID PDS-15-0468.R2]
  • Shirani, A, Zhao Y, Karim M, Evans C, Kingwell E, van der Kop M, Oger J, Gustafson P, Petkau J, Tremlett H. Multiple sclerosis in older adults: the clinical profile and impact of interferon beta treatment. Biomed Research International (accepted feb/2015)
  • Zhang T, Shirani A, Zhao Y, Karim, Gustafson P, Petkau J, Evans C, Kingwell E, van der Kop M, Zhu F, Oger J, Tremlett H. Beta-interferon exposure and onset of secondary progressive multiple sclerosis. European Journal of Neurology. 2015 [Accepted 13-Jan-2015; Manuscript ID: EJoN-14-1247.R1]
  • Evans C, Zhu F, Kingwell E, Shirani A, van der Kop ML, Petkau J, Gustafson P, Zhao Y, Oger J, Tremlett H. Association between beta-interferon exposure and hospital events in multiple sclerosis. Pharmacoepidemiol Drug Saf. 2014 Jun 21. doi: 10.1002/pds.3667
  • Shirani A, Zhao Y, Karim ME, Petkau J, Gustafson P, Evans C, Kingwell E, van der Kop M, Oger J, BC MS Clinic Neurologists, H. Tremlett. Investigation of heterogeneity in the association between interferon beta and disability progression in multiple sclerosis: an observational study Eur J Neurol. 2013 Dec 18. doi: 10.1111/ene.12324.
  • Shirani, A., Zhao, Y., Karim, M. E., Evans, C., Kingwell, E., van der Kop, M. L., Oger, J., Gustafson, P., Petkau, J., Tremlett, H. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012; 308(3): 247-256.

Presentation of research material (poster/seminar/lecture etc.)

  • Karim, E.M.; Gustafson, P.; Petkau, J.; Shirani, A.; van der Kop, M.; Kingwell, E.; Zhao, Y.; Evans, C.; Tremlett, H. "Marginal structural models for investigating long term effectiveness of a time-dependent treatment: An application to muliple sclerosis." To be Presented: 2011 Joint Statistical Meetings. Activity 87, Section on Statistics in Epidemiology
  • Evans, C.; Zhao,Y.; Shirani, A.; Kingwell, E.; vanderKop, M.; Karim, E.M.; Gustafson, P.; Petkau, J.; Tremlett, H. "The BeAMS Study: Long-term benefits and adverse effects of beta-interferons for multiple sclerosis: Impact on hospitalservices utilization." Proceedings of endMS Conference 2010. 6-9 December 2010. Whistler, BC

Page last revised: December 5, 2017